Immune Milieu and Genomic Alterations Set the Triple-Negative Breast Cancer Immunomodulatory Subtype Tumor Behavior.

Rubén Rodríguez-BautistaClaudia H Caro-SánchezPaula Cabrera-GaleanaGerardo J Alanis-FunesEverardo Gutierrez-MillánSantiago Ávila-RíosMargarita Matías-FlorentinoGustavo Reyes-TeránJosé Díaz-ChávezCynthia Villarreal-GarzaNorma Y Hernández-PedroAlette Ortega-GómezLuis Lara-MejíaClaudia Rangel-EscareñoOscar Arrieta

Published in: Cancers (2021)

the IM subtype showed a distinct immune microenvironment, as well as subtype-specific genomic alterations. Characterizing TNBC at a molecular and transcriptomic level might guide immune-based therapy in this subgroup of patients.

Keyphrases

patient reported outcomes
copy number
stem cells
end stage renal disease
randomized controlled trial
clinical trial
ejection fraction
chronic kidney disease
gene expression
mesenchymal stem cells
prognostic factors
bone marrow
open label
phase iii